Undisclosed solid tumor-associated antigen

The term "Undisclosed solid tumor-associated antigen" serves as a placeholder in the pharmaceutical industry for a proprietary molecular target that a company has not yet publicly named to protect its intellectual property (Nature Reviews Drug Discovery, 2023). These targets are typically proteins or glycoproteins expressed on the surface of solid tumor cells, such as those found in lung, breast, or pancreatic cancers, and are selected for their potential to facilitate targeted therapy (NIH National Cancer Institute). Because the specific identity of the molecule is confidential, its precise biological functions—such as involvement in cell signaling, proliferation, or apoptosis—remain unknown to the public during the early stages of drug development. These undisclosed antigens are commonly the focus of advanced therapeutic modalities, including antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies (Biopharma Dive, 2022). The primary therapeutic strategy involves using the antigen as a docking site to deliver cytotoxic agents or to engage the immune system specifically at the tumor site. Once the development reaches a certain milestone, the identity of the antigen is usually revealed, often proving to be a member of the B7 family, a receptor tyrosine kinase, or a specific cluster of differentiation (CD) marker.

Other names

Undisclosed tumor antigenProprietary tumor-associated antigenConfidential tumor target

The mechanism of action is dependent on the specific therapeutic modality (e.g., ADC, CAR-T, or monoclonal antibody) designed to bind the undisclosed antigen and induce tumor cell death.